SCHEMBL1406418

SCHEMBL1406418

CCc1cc2cc(C(=O)NC(=O)c3ccc(S(=O)(=O)NC(=N)N)cc3)c(=O)oc2cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F12 P00748 3/20 0.44
▸ F2 P00734 1/20 0.44
▸ F10 P00742 1/20 0.44
▸ PLG P00747 1/20 0.44
▸ F11 P03951 1/20 0.44
▸ CA12 O43570 8/20 0.41
▸ CA1 P00915 8/20 0.41
▸ CA2 P00918 8/20 0.41
▸ CA4 P22748 6/20 0.41
▸ CA5A P35218 6/20 0.41
▸ CA7 P43166 6/20 0.41
▸ CA5B Q9Y2D0 6/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAOB P27338 2/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406525 0.89 F12 (0.45) F12F2F10PLGF11
SCHEMBL1406413 0.81 CNR2 (0.44) F12F2F10PLGF11
SCHEMBL1406475 0.76 GPR35 (0.48) CA12CA1CA2CA4CA5A
SCHEMBL1406194 0.76 GPR35 (0.48) CA12CA1CA2CA4CA5A
SCHEMBL1406588 0.74 MAPT (0.39) CA12CA1CA2CA4CA5A
SCHEMBL1406460 0.69 GPR35 (0.58) CA12CA1CA2CA4CA5A
SCHEMBL1406447 0.67 ALDH1A1 (0.33) CA12CA1CA2KDM4EMAPT
SCHEMBL5171286 0.65 KDM4E (0.45) F12F2F10PLGF11
SCHEMBL1406745 0.64 GPR35 (0.52) CA12CA1CA2CA4CA5A
SCHEMBL1406450 0.64 GPR35 (0.49) CA12CA1CA2CA4CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 — — EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 — — US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 — — EP disclosed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 — — WO disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 — — US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR F12 928/4885F2 1342/4885F10 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback